Reviva to Present at the UBS Virtual CNS Day

Rhea-AI Summary

Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced that their CEO will participate in a Fireside Chat at the UBS Virtual CNS Day on March 18, 2024, focusing on therapies for CNS, inflammatory, and cardiometabolic diseases.

CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a Fireside Chat at the UBS Virtual CNS Day, taking place virtually March 18, 2024.

UBS Virtual CNS Day
    Format: Fireside Chat
    Date: Monday, March 18, 2024
    Time: 1:30 p.m. ET
    Location: Virtual

To register for the event, please click here or contact your UBS representative.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

Media Contact:
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783

FAQ

When is the UBS Virtual CNS Day Fireside Chat with Reviva Pharmaceuticals Holdings, Inc. CEO scheduled?

The Fireside Chat with Reviva Pharmaceuticals Holdings, Inc. CEO is scheduled for Monday, March 18, 2024, at 1:30 p.m. ET.

What are the areas of focus for Reviva Pharmaceuticals Holdings, Inc. in terms of therapy development?

Reviva Pharmaceuticals Holdings, Inc. focuses on developing therapies for central nervous system (CNS), inflammatory, and cardiometabolic diseases.

How can one register for the UBS Virtual CNS Day event featuring Reviva Pharmaceuticals Holdings, Inc.?

To register for the event, individuals can click on the provided link or contact their UBS representative.